Fisher Asset Management LLC Has $23.99 Million Position in Celldex Therapeutics, Inc. $CLDX

Fisher Asset Management LLC lifted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 12.8% in the third quarter, HoldingsChannel reports. The institutional investor owned 927,157 shares of the biopharmaceutical company’s stock after buying an additional 104,949 shares during the period. Fisher Asset Management LLC’s holdings in Celldex Therapeutics were worth $23,986,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Commodore Capital LP increased its position in shares of Celldex Therapeutics by 7.8% in the second quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock valued at $70,208,000 after acquiring an additional 250,000 shares during the last quarter. Bellevue Group AG grew its stake in Celldex Therapeutics by 7.7% in the second quarter. Bellevue Group AG now owns 3,307,569 shares of the biopharmaceutical company’s stock valued at $67,309,000 after purchasing an additional 235,954 shares in the last quarter. Vestal Point Capital LP increased its position in shares of Celldex Therapeutics by 781.0% during the 2nd quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company’s stock worth $35,612,000 after purchasing an additional 1,551,354 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Celldex Therapeutics by 5.2% during the 2nd quarter. Geode Capital Management LLC now owns 1,672,980 shares of the biopharmaceutical company’s stock worth $34,050,000 after purchasing an additional 83,174 shares in the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Celldex Therapeutics by 4.6% in the 3rd quarter. American Century Companies Inc. now owns 815,560 shares of the biopharmaceutical company’s stock valued at $21,099,000 after buying an additional 35,575 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CLDX. Stifel Nicolaus restated a “buy” rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Barclays upped their target price on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, January 21st. Finally, The Goldman Sachs Group boosted their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Celldex Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.50.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $28.94 on Wednesday. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -7.44 and a beta of 1.17. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $31.31. The stock has a fifty day moving average price of $25.80 and a 200-day moving average price of $25.58.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.22). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 41.67%. The company had revenue of $0.12 million during the quarter, compared to analyst estimates of $1.53 million. Research analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.